ERBB2 and neoplasm: Among patients with a luminal tumor type, only 1 out of 27 (3.7%) achieved pCR, whereas higher pCR rates were observed in the luminal/HER-2 co-expressing (5/7; 71.4%), HER-2 only (3/7; 42.9%), and triple-negative (2/9; 22.2%) subtypes.